Dashboard
1
The company has declared Positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 2,703.43 MM
- DEBT-EQUITY RATIO (HY) Lowest at 17.09 %
- INTEREST COVERAGE RATIO(Q) Highest at 2,467.55
2
With ROE of 14.35%, it has a attractive valuation with a 1.38 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 26,102 Million (Large Cap)
10.00
NA
5.00%
0.19
14.35%
1.34
Revenue and Profits:
Net Sales:
5,959 Million
(Quarterly Results - Jun 2026)
Net Profit:
922 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.51%
0%
10.51%
6 Months
3.41%
0%
3.41%
1 Year
-12.38%
0%
-12.38%
2 Years
10.25%
0%
10.25%
3 Years
-17.49%
0%
-17.49%
4 Years
15.25%
0%
15.25%
5 Years
-5.24%
0%
-5.24%
Humanwell Healthcare (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.20%
EBIT Growth (5y)
6.74%
EBIT to Interest (avg)
8.35
Debt to EBITDA (avg)
1.64
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.89
Tax Ratio
19.77%
Dividend Payout Ratio
42.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.79%
ROE (avg)
14.85%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.38
EV to EBIT
8.51
EV to EBITDA
6.97
EV to Capital Employed
1.32
EV to Sales
1.27
PEG Ratio
0.15
Dividend Yield
1.96%
ROCE (Latest)
15.48%
ROE (Latest)
14.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
5,959.50
5,926.50
0.56%
Operating Profit (PBDIT) excl Other Income
1,384.70
1,240.20
11.65%
Interest
56.10
74.00
-24.19%
Exceptional Items
-0.50
-0.80
37.50%
Consolidate Net Profit
921.50
798.60
15.39%
Operating Profit Margin (Excl OI)
190.70%
165.80%
2.49%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 0.56% vs -7.99% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 15.39% vs -1.09% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
23,835.30
25,312.20
-5.83%
Operating Profit (PBDIT) excl Other Income
4,596.20
3,905.50
17.69%
Interest
298.80
379.60
-21.29%
Exceptional Items
-376.50
-261.00
-44.25%
Consolidate Net Profit
2,492.50
1,778.30
40.16%
Operating Profit Margin (Excl OI)
149.10%
113.10%
3.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -5.83% vs 3.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 40.16% vs -36.83% in Dec 2024
About Humanwell Healthcare (Group) Co., Ltd. 
Humanwell Healthcare (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






